Expertos Invitados





EVALUACION DE NUEVOS AGENTES PARA EL CANCER DE PANCREAS

(especial para SIIC © Derechos reservados)
La gemcitabina se mantiene como el patrón de referencia en el tratamiento del cáncer de páncreas exocrino avanzado. Los nuevos agentes citotóxicos solos o en combinación con gemcitabina pueden mejorar el control del tumor y, posiblemente, aumentar la supervivencia.
evans9.jpg Autor:
T. r. jeffry Evans
Columnista Experto de SIIC

Institución:
Centre of Oncology and Applied Pharmacology University of Glasgow Cancer Research UK Beatson Laboratories Glasgow, UK

Artículos publicados por T. r. jeffry Evans
Recepción del artículo
8 de Septiembre, 2004 		Aprobación
20 de Septiembre, 2004
Primera edición
1 de Agosto, 2005 		Segunda edición, ampliada y corregida
7 de Junio, 2021

EVALUACION DE NUEVOS AGENTES PARA EL CANCER DE PANCREAS

Resumen
El carcinoma del páncreas exocrino es la cuarta causa más frecuente de muerte por cáncer en el Reino Unido. La mayor parte de los casos se presentan como una enfermedad inoperable con un promedio de supervivencia de solamente unos pocos meses en pacientes con enfermedad metastásica. En la actualidad la gemcitabina es el tratamiento de elección en los pacientes con enfermedad avanzada. En esta revisión se remarca la necesidad de desarrollar nuevas estrategias terapéuticas que mejoren la supervivencia en esta patología y se discute la combinación de aquellos regímenes quimioterapéuticos evaluados previamente. El camino más promisorio para los estadios avanzados de la enfermedad parece ser el diseño de nuevos agentes terapéuticos que se obtengan de la profundización del conocimiento de la biología del cáncer pancreático.

Palabras clave
Páncreas, gemcitabina, quimioterapia, terapias moleculares


Artículo completo
(castellano)
Extensión:  +/-9.83 páginas impresas en papel A4
Exclusivo para suscriptores/assinantes

EVALUATION OF NOVEL AGENTS IN PANCREATIC CANCER

Abstract
Carcinoma of the exocrine pancreas is the fourth commonest cause of cancer deaths in the UK. Most cases present with inoperable disease with a median survival of only a few months in patients with metastatic disease. Currently single-agent gemcitabine is the treatment of choice in patients with advanced disease. This review highlights the challenges in developing therapeutic strategies to improve survival in this disease and discusses the various combination chemotherapy regimens that have been evaluated. Exploiting our understanding of the biology of pancreatic cancer to design novel agents seems to hold the greatest promise in advanced disease.

Key words
Pancreas, gemcitabine, chemotherapy, molecular therapies


Full text
(english)
 para suscriptores/ assinantes
Clasificación en siicsalud
Artículos originales > Expertos del Mundo >
página   www.siicsalud.com/des/expertocompleto.php/

Especialidades
Principal: Oncología
Relacionadas: Farmacología, Gastroenterología, Medicina Farmacéutica, Medicina Interna



Comprar este artículo
Extensión: 9.83 páginas impresas en papel A4

file05.gif (1491 bytes) Artículos seleccionados para su compra



Enviar correspondencia a:
Evans, TRJ
Patrocinio y reconocimiento:
Agradecimiento: El autor desea expresar su agradacimiento a Fiona Conway –secretaria asistente– por su ayuda en la preparación de este manuscrito.
Bibliografía del artículo
  1. Williamson RCN. Pancreatic Cancer: the greatest oncological challenge. Br Med J 1988; 296:445-446.
  2. Cancer of the Pancreas Task Force Group. Staging of cancer of the pancreas. Cancer 1981; 47:1631-1637.
  3. Carter SK. The integration of chemotherapy into a combined modality approach for cancer treatment: VI. Pancreatic adenocarcinoma. Cancer Treat Rev 1975; 3:193-214.
  4. Moertel CG. Chemotherapy for gastrointestinal cancer. Clin Gastroenterol 1976; 5:777-793.
  5. Bernard S, Noble S, Wilcosky T, et al. A phase II study of ifosfamide (IFOS) plus N-acetyl cysteine (NAC) in metastatic measurable pancreatic adenocarcinoma (abstract). Proc Am Soc Clin Oncol 1986; 5:328.
  6. Wils J, Bleiberg H, Blijham G, et al. Phase II study of epirubicin in advanced adenocarcinoma of the pancreas. Eur J Cancer Clin Oncol 1985; 21:191-194.
  7. Wils J, Kok T, Wagener OJ, et al. Activity of cisplatin in adenocarcinoma of the pancreas. Eur J Cancer 1993; 29: 203-204.
  8. Kovach JS, Moertel CG, Schuft AJ, et al. A controlled study of combined 1,3-bio(2-chlorethyl)-1-nitrosurea and 5-fluorouracil therapy for advanced gastric and pancreatic cancer. Cancer 1974; 33: 563-567.
  9. Buroker T, Kim PN, Groppe C, et al. 5-FU infusion with mitomycin C vs 5-FU infusion with methyl CCNU in the treatment of advanced upper gastrointestinal cancer. Cancer 1979, 44: 1215-1221.
  10. Oster MW, Gray R, Panasci L, et al. Chemotherapy for advanced pancreatic cancer: A comparison of 5-fluorouracil, adriamycin and mitomycin C (FAM) with 5-fluorouracil, streptozotcin and mitomycin C (FSM). Cancer 1986; 57: 29-33.
  11. Evans, TRJ, Lofts FJ, Mansi JL, et al. A phase II study of continuous-infusion 5-fluorouracil with cisplatin and epirubicin in inoperable pancreatic cancer. Br J Cancer 1996; 73: 1260-1264.
  12. Hausen R, Quebbman E, Ritch P, et al. Continous 5-fluorouracil infusion in carcinoma of the pancreas. Am J Med Sci 1988; 295: 91-93.
  13. Mallinson GN, Rake MO, Cocking JB, et al. Chemotherapy in pancreatic cancer: results of a controlled, prospective, randomised, multicentre trial. Br Med J 1980; 281: 1589-1591.
  14. Palmer KR, Kerr M, Knowles G, et al. Chemotherapy prolongs survival in inoperable pancreatic carcinoma. Br J Surg 1994; 81: 882-885.
  15. Vasey PA and Evans J. Principles of chemotherapy and drug development. In: Treatment of Cancer (eds. Price P, Sikora K), Arnold Publishers, London, 2002, 103-129.
  16. Cullinan SA, Moertel CG, Fleming TR, et al. A comparison of three chemotherapeutic regimens in the treatment of advanced pancreatic and gastric carcinoma. JAMA 1985; 253: 2061-2067.
  17. Rothenberg ML, Moore MJ, Cripps MC, et al. A phase II trial of gemcitabine in patients with 5-FU-refractory pancreas cancer. Ann Oncol 1996; 7: 347-535.
  18. Grindey GB, Hertel LW, Plunkett W. Cytotoxicity and anti-tumour activity of 2’2’-difluorodeoxycytidine (Gemcitabine). Cancer Invest 1990; 8: 313-318.
  19. Hertel W, Boder GB, Kroin JS, et al. Evaluation of the anti-tumour activity of gemcitabine (2’2’-difluorodeoxycytidine). Cancer Res 1990; 50: 4417-4422.
  20. Heinemann V, Hertel L, Grindey GB, et al. Comparison of the cellular pharmacokinetics and toxicity of 2’2’-difluorodeoxycytidine and 1-b-D-arabinofuranasyl cytosine. Cancer Res 1988; 48: 4024-4031.
  21. Huang P, Chubb S, Hertel W, et al. Action of 2’2’-difluorodeoxycytidine on DNA synthesis. Cancer Res 1991; 51: 6110-6117.
  22. Ghandi V, Plunkett W. Modulatory activity of 2’2’-difluorodeoxycytidine on the phosphorylation and cytotoxicity of arabinosyl nucleosides. Cancer Res 1990; 50: 3695-3680.
  23. Casper ES, Green MR, Kelsen DP, et al. Phase II trial of gemcitabine (2’2-difluorodeoxycytidine) in patients with adenocarcinoma of the pancreas. Invest New Drugs 1994; 12: 29-34.
  24. Burris HA, Moore MJ, Andersen J, et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: A randomised trial. J Clin Oncol 1997; 15: 2403-2413.
  25. Cartwright TH, Cohn A, Varkey JA et al. Phase II study of oral capecitabine in patients with advanced or metastatic pancreatic cancer. J Clin Oncol 2002; 20: 160-164.
  26. Needle MN. Safety experience with IMC-C225, an anti-epidermal growth factor receptor antibody. Sem Oncol 2002; 29: 55-60.
  27. Hecht JR, Bedford R, Abbruzzese JL, et al. A phase I/II trial of intratumoral endoscopic ultrasound injection of ONYX-015 with intravenous gemcitabine in unresectable pancreatic carcinoma. Clin Cancer Res 2003; 9: 555-561.
  28. Kanat O, Eurensel T, Kurt E, et al. Treatment of metastatic pancreatic cancer with a combination of gemcitabine and 5-fluorouracil: a single center phase II study. Tumori 2004; 90: 192-195.
  29. Murad AM, Guimaeres RC, Aragao BC, et al. Phase II trial of the use of gemcitabine and 5-fluorouracil in the treatment of advanced pancreatic and biliary tract cancer. Am J Clin Oncol 2003; 26: 151-154.
  30. Barone C, Cassano A, Corsi DC, et al. Weekly gemcitabine and 24-hour infusional 5-fluorouracil in advanced pancreatic cancer: a phase I-II study. Oncology 2003; 64: 139-145.
  31. Correale P, Messinese S, Marsili S, et al. A novel bi weekly pancreatic cancer treatment schedule with gemcitabine, 5-fluorouracil and folinic acid. Br J Cancer 2003; 89: 239-242.
  32. Marantz A, Jovtis S, Almira E, et al. Phase II study of gemcitabine, 5-fluorouracil, and leucovorin in patients with pancreatic cancer. Sem Oncol 2001; 28: 44-49.
  33. Louvet C, Andre T, Hammel P, et al. Phase II trial of bimonthly leucovorin, 5-fluorouracil and gemcitabine for advanced pancreatic adenocarcinoma (FOLFUGEM). Ann Oncol 2001; 12: 675-679.
  34. Stathopoulos GP, Syrigos K, Polyzos A, et al. Front-line treatment of inoperable or metastatic pancreatic cancer with gemcitabine and capecitabine: an intergroup, multicenter, phase II study. Ann Oncol 2004; 15: 224-229.
  35. Hess V, Salzberg M, Borner M, et al. Combining capecitabine and gemcitabine in patients with advanced pancreatic carcinoma: a phase I/II trial. J Clin Oncol 2003; 21: 66-68.
  36. Lee J, Park JO, Kim WS, et al. Phase II study of gemcitabine combination with uracil – tegafur in metastatic pancreatic cancer. Oncology 2004; 66: 32-37.
  37. Feliu J, Mel R, Borrega P, et al. Phase II study of a fixed dose-rate infusion of gemcitabine associated with uracil/tegafur in advanced carcinoma of the pancreas. Ann Oncol 2003; 13: 1756-1762.
  38. Kim TW, Kang HJ, Ahn JH, et al. Phase II study of gemcitabine, UFT and leucovorin in patients with advanced pancreatic cancer. Acta Oncol 2002; 41: 689-694.
  39. Berlin JD, Catalano P, Thomas JP, et al. Phase III study of gemcitabine in combination with fluorouracil versus gemcitabine alone in patients with advanced pancreatic carcinoma: Eastern Cooperative Oncology Group Trial E2297. J Clin Oncol 2002; 20: 3270-3275.
  40. Alberts SR, Townley PM, Goldberg RM, et al. Gemcitabine and oxaliplatin for metastatic pancreatic adenocarcinoma: a North Central Cancer Treatment Group phase II study. Ann Oncol 2003; 14: 580-585.
  41. Alberts SR, Townley PM, Goldberg RM, et al. Gemcitabine and oxaliplatin for patients with advanced or metastatic pancreatic cancer: a North Central Cancer Treatment Group Phase I study. Ann Oncol 2002; 13: 553-557.
  42. Louvet C, Andre T, Lledo G, et al. Gemcitabine combined with oxaliplatin in advanced pancreatic adenocarcinoma: final results of a GERCOR multicenter phase II study. J Clin Oncol 2002; 20: 1512-1518.
  43. Stathopoulos GP, Rigatos SK, Dimopoulos MA, et al. Treatment of pancreatic cancer with a combination of irinotecan (CPT-11) and gemcitabine: a multicenter phase II study by the Greek Cooperative Group for Pancreatic Cancer. Ann Oncol 2003; 14: 388-394.
  44. Rocha Lima CM, Savarese D, Bruckner H, et al. Irinotecan plus gemcitabine induces both radiographic and CA19-9 tumor marker responses in patients with previously untreated advanced pancreatic cancer. J Clin Oncol 2002; 20: 1182-1191.
  45. Shepard LC, Levy DE, Berlin JD, et al. Phase II study of gemcitabine in combination with docetaxel in patients with advanced pancreatic carcinoma (E1298). A trial of the Eastern Cooperative Oncology Group. Oncology 2004; 66: 303-309.
  46. Schneider BP, Ganjoo KN, Seitz OE, et al. Phase II study of gemcitabine plus docetaxel in advanced pancreatic cancer: a Hoosier Oncology Group study. Oncology 2003; 65: 218-223.
  47. Ryan DP, Kulke MH, Fuchs CS, et al. A phase II study of gemcitabine and docetaxel in patients with metastatic pancreatic carcinoma. Cancer 2002; 94: 97-103.
  48. Cascinu S, Labianca R, Catalano V, et al. Weekly gemcitabine and cisplatin chemotherapy: a well-tolerated but ineffective chemotherapeutic regimen in advanced pancreatic cancer patients. A report from the Italian Group for the Study of Digestive Tract Cancer (GESCAD). Ann Oncol 2003; 14: 205-208.
  49. Philip PA, Zalupski MM, Vaitkevicius VK, et al. Phase II study of gemcitabine and cisplatin in the treatment of patients with advanced pancreatic carcinoma. Cancer 2001; 92: 569-577.
  50. Neri B, Cini G, Doni L, et al. Weekly gemcitabine plus epirubicin as effective chemotherapy for advanced pancreatic cancer: a multicenter phase II study. Br J Cancer 2002; 87: 497-501.
  51. Ianniello GP, Orditura M, Rossi A, et al. Gemcitabine plus epirubicin in advanced pancreatic cancer: a phase II multicenter trial. Oncol Reports 2001; 8: 1111-1115.
  52. Kralidis E, Aebi S, Friess H, et al. Activity of raltitrexed and gemcitabine in advanced pancreatic cancer. Ann Oncol 2003; 14: 574-579.
  53. Tomao S, Romiti A, Massidda B, et al. A phase II study of gemcitabine and tamoxifen in advanced pancreatic cancer. Anticancer Res 2002; 22: 2361-2364.
  54. Corrie P, Mayer A, Shaw J, et al. Phase II study to evaluate combining gemcitabine with flutamide in advanced pancreatic cancer patients. Br J Cancer 2002; 87: 716-719.
  55. Rachamalla R, Malamud S, Grossbard ML, et al. Phase I dose-finding study of biweekly irinotecan in combination with fixed doses of 5-fluorouracil/leucovorin, gemcitabine and cisplatin (G-FLIP) in patients with advanced pancreatic cancer or other solid tumors. Anti-Cancer Drugs 2004; 15: 211-217.
  56. Kozuch P. Grossbard ML, Barzdins A, et al. Irinotecan combined with gemcitabine, 5-fluorouracil, leucovorin, and cisplatin (G-FLIP) is an effective and non cross-resistant treatment for chemotherapy refractory metastatic pancreatic cancer. Oncologist 2001; 6: 488-495.
  57. Novarino A, Chiappino I, Bertelli GF, et al. Phase II study of cisplatin, gemcitabine and 5-fluorouracil in advanced pancreatic cancer. Ann Oncol 2004; 15: 474-477.
  58. El-Rayes BF, Zalupski MM, Shields AF, et al. Phase II study of gemcitabine, cisplatin and infusional fluorouracil in advanced pancreatic cancer. J Clin Oncol 2003; 21: 2920-2925.
  59. Petty RD, Nicolson MC, Skaria S, et al. A phase II study of mitomycin-C, cisplatin and protracted infusional 5-fluorouracil in advanced pancreatic carcinoma: efficacy and low toxicity. Ann Oncol 2003; 14: 1100-1105.
  60. Colucci G, Guiliani F, Gebbia V, et al. Gemcitabine alone or with cisplatin for the treatment of patients with locally advanced and/or metastatic pancreatic carcinoma: a prospective, randomised phase III study of the Gruppo Oncoliga del’Italia Meridionale. Cancer 2002; 94: 902-910.
  61. Tempero M, Plunkett W, Ruiz van Haperen V, et al. Randomised phase II comparison of dose-intense gemcitabine: thirty-minute infusion and fixed dose rate infusion in patients with pancreatic adenocarcinoma. J Clin Oncol 2003; 21: 3402-3408.
  62. Hruban RH, Goggins M, Parsons J, et al. Progression model for pancreatic cancer. Clin Cancer Res 2000; 6: 2969-2972.
  63. Bos JL. Ras oncogenes in human cancer: a review. Cancer Res 1989; 49: 4682-4689.
  64. Almoguerra L, Shibata D, Forrester K, et al. Most human carcinomas of the exocrine pancreas contain mutant c-k-ras genes. Cell 1988; 53: 549-554.
  65. Caldas C, Hahn SA, da Costa LT, et al. Frequent somatic mutations and homozygous deletions of the p16 (MTS1) gene in pancreatic adenocarcinoma. Nat Genetics 1994; 8: 27-32.
  66. Schutte M, Hruban RH, Geradts J, et al. Abrogation of the Rb/p16 tumor-suppressive pathway in virtually all pancreatic carcinomas. Cancer Res 1997; 57: 3126-3130.
  67. Hahn SA, Schutte M, Hoque ATMS, et al. DPC4, a candidate tumor-suppressor gene at 18q21.1. Science 1996; 271: 350-353.
  68. Su GH, Hilgers W, Shehker MC, et al. Alterations in pancreatic, biliary, and breast carcinomas support MKK4 as a genetically targeted tumor-suppressor gene. Cancer Res 1998; 58: 2339-2342.
  69. Goggins M, Hruban, RH, Kern SE. BRCA 2 is inactivated late in the development of pancreatic intra-epithelial neoplasia: evidence and implications. Am J Pathol 2000; 156: 1767-1771.
  70. Korc M. Role of growth factors in pancreatic cancers. Surg Oncol Clin N Am 1998; 7: 25-41.
  71. Luo J, Guo P, Matsuda K, et al. Pancreatic cancer cell-derived vascular endothelial growth factor is biologically active in vitro and enhances tumorigenicity in vivo. Int J Cancer 2001; 92: 361-369.
  72. Shi Q, Le X, Peng Z, et al. Constitutive Sp1 activity is essential for differential constitutive expression of vascular endothelial growth factor in human pancreatic adenocarcinoma. Cancer Res 2001; 61: 4143-4154.
  73. Yamanaka Y, Freiss H, Buckler M, et al. Overexpression of acidic and basic fibroblast growth factors in human pancreatic cancer correlates with advanced tumor stage. Cancer Res 1993; 53: 5289-5296.
  74. Kleeff J, Ishiwata T, Freiss H, et al. The TGF- signalling inhibitor Smad7 enhances tumorigenicity in pancreatic cancer. Oncogene 1999; 18: 5363-5372.
  75. Watanabe N, Tsuji N, Koboyashi D, et al. Endogenous tumor necrosis factor functions as a resistant factor against hyperthermic cytotoxicity in pancreatic carcinoma cells via enhancement of the heat shock element-binding activity of heat shock factor 1. Chemotherapy 1997; 43: 406-414.
  76. Blanchard JA 2nd, Barve S, Joshi-Barve S, et al. Cytokine production by CAPAN-1 and CAPAN-2 cell lines. Dig Dis Sci 2000; 45: 927-932.
  77. Saito K, Ishikura H, Kishimoto T, et al. Interleukin-6 produced by pancreatic carcinoma cells enhances humoral immune responses against tumor cells: a possible event in tumor regression. Int J Cancer 1998; 75: 284-289.
  78. Shi Q, Abbruzzese J, Huang S, et al. Constitutive and inducible interleukin-8 expression by hypoxia and acidosis renders human pancreatic cancer cells more tumorigenic and metastatic. Clin Cancer Res 1999; 5: 3711-3721.
  79. Kato K, Cox AD, Hisaka MM, et al. Isoprenoid addition to ras protein is the critical modification for its membrane association and transforming activity. Proc Natl Acad Sci USA 1992; 89: 6403-6407.
  80. Manne V, Roberts D, Tobin A, et al. Identification and preliminary characterization of protein-cysteine farnesyltransferase. Proc Natl Acad Sci USA 1990; 87: 7541-7545.
  81. van Cutsem E, van de Velde H, Karasek P, et al. Phase III trial of gemcitabine plus tipifarnib compared with gemcitabine plus placebo in advanced pancreatic cancer. J Clin Oncol 2004; 22: 1430-1438.
  82. Reuter CWM, Morgan MA, Bergman L. Targeting Ras signalling pathway: a rational, mechanism-based treatment for hematologic malignancies. Blood 2000; 96: 1655-1699.
  83. Cox AD, Der CJ. Farnesyltransferase inhibitors and cancer treatment: targeting simply Ras Biochim Biopshys Acta 1997; 1333: F51-F71.
  84. Adjei AA. Protein farnesyltransferase as a target for the development of anticancer agents. Drugs of the Future 2000; 25: 1069-1079.
  85. Lebowitz PF, Prendergast GC. Non-Ras targets of farnesyltransferase inhibitors: focus on Rho. Oncogene 1998; 17: 1439-1445.
  86. Ashar HR, James L, Gray K, et al. FTIs block the farnesylation of CENP-E and CENP-F and alter the association of CENP-E with the microfubules. J Biol Chem 2000; 275: 30451-30457.
  87. Jiang K, Coppola D, Crespo NO, et al. The phosphinositide 3-OH kinase AKt2 pathway as a critical target for farnesyltransferase inhibitor-induced apoptosis. Mol Cell Biol 2000; 20: 139-148.
  88. Bramhall SR, Rosemurgy A, Brown PD, et al. Marimastat as first-line therapy for patients with unresectable pancreatic cancer: a randomized trial. J Clin Oncol 2001; 19: 3447-3455.
  89. Bramhall SR, Schulz J, Nemnaitis J, et al. A double-blind placebo-controlled, randomized study comparing gemcitabine and marimastat with gemcitabine and placebo as first-line therapy in patients with advanced pancreatic cancer. Br J Cancer 2002; 87: 161-167.
  90. Moore MJ, Hamm J, Dancey J, et al. Comparison of gemcitabine versus matrix metalloprotinease inhibitor BAY 12-9566 in patients with advanced or metastatic adenocarcinoma of the pancreas: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 2003; 21: 3296-3302.
  91. Hess KR, Abbruzzese JL. Editorial: Matrix metalloproteinase inhibition of pancreatic cancer: matching mechanism of action to clinical trial design. J Clin Oncol 2001; 19:3445-3446.
 
 
 
 
 
 
 
 
 
 
 
 
Está expresamente prohibida la redistribución y la redifusión de todo o parte de los contenidos de la Sociedad Iberoamericana de Información Científica (SIIC) S.A. sin previo y expreso consentimiento de SIIC.
ua31618
Inicio/Home

Copyright siicsalud © 1997-2024 ISSN siicsalud: 1667-9008